News

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices ProSomnus Sleep ...
Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as ...
ProSomnus devices are the only Oral Appliance Therapy devices to demonstrate efficacy on par with CPAP for mild to moderate Obstructive Sleep Apnea and adherence that exceeds the recommended ...
With more than 150,000 patients treated, ProSomnus’s devices are the most prescribed oral appliance therapy in the U.S. To learn more, visit www.ProSomnus.com .
ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.”— Len Liptak, CEO, ProSomnus Sleep ...
PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced ...
Obstructive sleep apnea (OSA) oral appliance manufacturer ProSomnus Sleep Technologies has debuted as a publicly traded company after combining with Lakeshore Acquisition I. On December 7, ProSomnus ...
PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of ...
ProSomnus Inc OSA has completed enrollment in the FLOSAT study, a head-to-head, crossover study comparing the effectiveness of precision oral appliance therapy (OAT) as first-line treatment versus ...
Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “OSA” SAN FRANCISCO, Dec. 06, 2022 (GLOBE ...
SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVO TM ...